metaOBS - - Real World Evidence KB

Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament	Trials	Summary Endpoints
Treament	Trials	Demonstrated or suggested benefit	Inconclusive results	Uncertain results	Safety results
Immunostimulants drugs	80	demonstrated 12 % decrease in death D28 demonstrated 11 % decrease in deaths demonstrated 14 % decrease in clinical deterioration demonstrated 11 % increase in clinical improvement suggested 78 % increase in clinical improvement (28-day) demonstrated 15 % increase in clinical improvement (time to event analysis only) suggested 3.0-fold increase in viral clearance suggested 58 % increase in viral clearance by day 7 suggested 40 % decrease in ICU admission	inconclusive results for: 14-days deaths; death or transfer to ICU; deaths (time to event analysis only); clinical improvement (14-day); clinical improvement (7-day); death or ventilation; hospital discharge; hospitalization; mechanical ventilation; mechanical ventilation (time to event analysis only); radiologic improvement (14-day); Recovery (time to event analysis only); viral clearance (time to event analysis only); viral clearance by day 14; off oxygenation; recovery; composite safety outcome ; related SAE (TRSAE); serious adverse events; superinfection; adverse events	-	-
Immunosuppressants drugs	69	demonstrated 30 % decrease in clinical deterioration demonstrated 25 % increase in clinical improvement suggested 37 % increase in clinical improvement (14-day) demonstrated 15 % increase in clinical improvement (time to event analysis only) demonstrated 16 % decrease in death or ventilation suggested 19 % decrease in mechanical ventilation	inconclusive results for: death or transfer to ICU; deaths (time to event analysis only); clinical improvement (21-day); clinical improvement (28-day); clinical improvement (7-day); hospital discharge; radiologic improvement (14-day); viral clearance (time to event analysis only); ICU admission; recovery; related AE (TRAE); serious adverse events; acute kidney injury ; adverse events; elevated liver enzymes; Myocardial infarction ; venous thromboembolism	suggested 50 % decrease in superinfection but the degree if certainty is unassessable suggested 84 % decrease in arrhythmia but the degree if certainty is unassessable	demonstrated 24 % decrease in death D28 with safety concern demonstrated 23 % decrease in deaths with safety concern
anti-inflammatory therapies	26	suggested 82 % decrease in clinical deterioration suggested 81 % decrease in serious adverse events	inconclusive results for: death D28; death or transfer to ICU; deaths; deaths (time to event analysis only); clinical improvement (28-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; mechanical ventilation; viral clearance ; viral clearance by day 7; ICU admission; adverse events; cardiovascular or renal events	suggested 10.3-fold increase in clinical improvement but the degree if certainty is unassessable suggested 10.3-fold increase in clinical improvement (14-day) but the degree if certainty is unassessable suggested 6.7-fold increase in clinical improvement (7-day) but the degree if certainty is unassessable suggested 2.9-fold increase in radiologic improvement (14-day) but the degree if certainty is unassessable suggested 3.5-fold increase in recovery but the degree if certainty is unassessable	-
corticosteroids	22	demonstrated 15 % decrease in deaths	inconclusive results for: death D28; death or transfer to ICU; deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; mechanical ventilation; ICU admission; serious adverse events; superinfection	suggested 4.9-fold increase in radiologic improvement (14-day) but the degree if certainty is unassessable suggested 78 % increase in viral clearance but the degree if certainty is unassessable suggested 78 % increase in viral clearance (time to event analysis only) but the degree if certainty is unassessable	-
Kinase inhibitors	3	none	-	-	-
leflunomide	1	none	inconclusive results for: deaths; clinical deterioration; viral clearance ; related SAE (TRSAE); adverse events	-	-
Apilimod	0	-	-	-	-
inhaled corticosteroids	0	-	-	-	-
meplazumab	0	-	-	-	-
pirfenidone	0	-	-	-	-
Polyinosinic-Polycytidylic Acid	0	-	-	-	-
sargramostim	0	-	-	-	-
statins	0	-	-	-	-
thymosin	0	-	-	-	-